HCP
DMK

Hexagon Capital Partners’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Hexagon Capital Partners’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-71
Closed -$5K – 913
2021
Q3 		$5K Hold
71
– – ﹤0.01% 685
2021
Q2 		$6K Hold
71
– – ﹤0.01% 632
2021
Q1 		$4K Sell
71
-29
-29% -$2.26K ﹤0.01% 630
2020
Q4 		$3K Hold
100
– – ﹤0.01% 623
2020
Q3 		$4K Buy
+100
New +$5.93K ﹤0.01% 561

Other funds holding DMK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hexagon Capital Partners's DMK Position: Q4 2021 in Review

Hexagon Capital Partners sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2021, closing a stake of 71 shares — an estimated $5K sold.

Hexagon Capital Partners first reported a position in DMK in Q3 2020 and held it in 5 quarters. The position peaked at $6K in Q2 2021. 49 funds tracked by Wall St. Rank hold DMK as of Q4 2021.

  • Hexagon Capital Partners reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2021 after selling out during the quarter.
  • Hexagon Capital Partners sold 71 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2021, an estimated $5K.
  • Hexagon Capital Partners first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2020 and held it in 5 quarters.
  • Hexagon Capital Partners's DMK Pharmaceuticals Corporation Common Stock position peaked at $6K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2021.

Based on Hexagon Capital Partners's 13F filing for Q4 2021, filed 27 Jan 2022.